~5 spots leftby Jun 2025

ALM-488 for Nerve Visualization during Head and Neck Surgery

Recruiting in Palo Alto (17 mi)
+6 other locations
RO
Overseen byRyan Orosco, MD
Age: Any Age
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 3
Recruiting
Sponsor: Alume Biosciences, Inc.
Disqualifiers: Radiation, Cardiac rhythm, Renal impairment, others
No Placebo Group
Pivotal Trial (Near Approval)
Prior Safety Data
Approved in 1 Jurisdiction

Trial Summary

What is the purpose of this trial?

This trial tests ALM-488, a tool that helps doctors see nerves better, in patients having head and neck surgery. It highlights nerves in real-time to avoid nerve damage.

Do I need to stop my current medications to join the trial?

The trial information does not specify whether you need to stop taking your current medications. Please consult with the study team for guidance.

What data supports the effectiveness of the treatment ALM-488 for nerve visualization during head and neck surgery?

Research on similar treatments, like the use of fluorescently labeled peptides, shows they can help identify and protect nerves during surgery, reducing the risk of nerve damage. This suggests that ALM-488, which is also a fluorescent agent, might be effective in helping surgeons see nerves better during head and neck surgeries.12345

How is the drug ALM-488 unique for nerve visualization during head and neck surgery?

ALM-488 is unique because it is a fluorescently labeled peptide specifically designed to help surgeons see nerves more clearly during surgery, reducing the risk of accidental nerve damage. This is different from traditional methods that rely on white light or nerve monitoring devices, as it provides direct visual guidance.34678

Research Team

RO

Ryan Orosco, MD

Principal Investigator

University of New Mexico

Eligibility Criteria

This trial is for individuals at least 16 years old who are scheduled for head and neck surgery, specifically parotidectomy, thyroidectomy, or cervical neck dissection. Participants must be able to follow the study procedures and provide consent. They should use contraception during the study if sexually active. Exclusions include allergy to fluorescein or ALM-488, prior radiation/surgery in the area, uncontrolled heart rhythm issues, severe kidney impairment, unresolved high-grade toxicity from cancer therapy, severe allergies or conditions affecting study participation.

Inclusion Criteria

I can become pregnant and agree to regular pregnancy tests during the study.
My main surgery was on my salivary gland, thyroid, or neck.
Willing and able to comply with all study procedures
See 4 more

Exclusion Criteria

I have had surgery or radiation on the area to be operated on.
I have side effects from cancer treatment that are not severe, except for hair loss or mild nerve pain.
I haven't had severe heart failure, a heart attack, or stroke in the last 6 months.
See 9 more

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive ALM-488 infusion for intraoperative nerve visualization during head and neck surgery

During surgery

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

  • ALM-488 (Fluorescent Dye)
Trial OverviewThe trial is testing ALM-488's ability to help surgeons see nerves more clearly during head and neck surgeries by comparing two methods: using a combination of white light reflectance with fluorescence overlay versus standard white light reflectance alone.
Participant Groups
4Treatment groups
Experimental Treatment
Group I: ALM-488-002b WLR with FL OverlayExperimental Treatment2 Interventions
Patients without a preoperative diagnosis of malignancy will be assigned to study ALM-488-002b. All patients will receive ALM-488 infusion. Intraoperative nerve visualization will be performed using WLR with FL Overlay.
Group II: ALM-488-002b WLR onlyExperimental Treatment2 Interventions
Patients without a preoperative diagnosis of malignancy will be assigned to study ALM-488-002b. All patients will receive ALM-488 infusion. Intraoperative nerve visualization will be performed using WLR only.
Group III: ALM-488-002a WLR with FL OverlayExperimental Treatment2 Interventions
Patients with a preoperative diagnosis of malignancy will be assigned to study ALM-488-002a. All patients will receive ALM-488 infusion. Intraoperative nerve visualization will be performed using WLR with FL Overlay.
Group IV: ALM-488-002a WLR onlyExperimental Treatment2 Interventions
Patients with a preoperative diagnosis of malignancy will be assigned to study ALM-488-002a. All patients will receive ALM-488 infusion. Intraoperative nerve visualization will be performed using WLR only.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Alume Biosciences, Inc.

Lead Sponsor

Trials
4
Recruited
390+

Ergomed

Industry Sponsor

Trials
11
Recruited
3,300+

Findings from Research

Intraoperative facial nerve monitoring (FNM) significantly reduces the incidence of immediate postoperative facial nerve weakness in patients undergoing primary parotidectomy, with a decrease from 34.9% in unmonitored cases to 22.5% in monitored cases.
However, FNM does not significantly affect the long-term risk of permanent facial nerve weakness, as the rates were similar between monitored (3.9%) and unmonitored (7.1%) groups.
Facial nerve monitoring during parotidectomy: a systematic review and meta-analysis.Sood, AJ., Houlton, JJ., Nguyen, SA., et al.[2021]
The use of fluorescently labeled nerve binding peptide NP41 during parotid gland cancer surgery in mice improved the identification and preservation of facial nerves compared to traditional white light methods.
Postoperative assessments indicated that facial nerve function was better preserved with fluorescent guidance, suggesting that NP41 can enhance surgical outcomes by reducing the risk of nerve injury.
Improved facial nerve identification during parotidectomy with fluorescently labeled peptide.Hussain, T., Nguyen, LT., Whitney, M., et al.[2018]
In a study of 100 patients undergoing middle ear and mastoid surgeries, intraoperative facial nerve monitoring (IOFNM) revealed that 43% of cases showed surgical dehiscence, indicating potential risk to the facial nerve during surgery.
The study established that an electrical stimulation threshold of 0.7 mA is effective for initial screening, while 0.4 mA is recommended for further exploration, ensuring better identification and protection of the facial nerve during these procedures.
Systematic facial nerve monitoring in middle ear and mastoid surgeries: "surgical dehiscence" and "electrical dehiscence".Choung, YH., Park, K., Cho, MJ., et al.[2019]

References

Facial nerve monitoring during parotidectomy: a systematic review and meta-analysis. [2021]
Intraoperative monitoring of marginal mandibular nerve during neck dissection. [2019]
Improved facial nerve identification during parotidectomy with fluorescently labeled peptide. [2018]
Systematic facial nerve monitoring in middle ear and mastoid surgeries: "surgical dehiscence" and "electrical dehiscence". [2019]
Predicting postoperative facial nerve paralysis by using intraoperative nerve monitoring during parotid surgery. [2023]
A newly designed nerve monitor for microneurosurgery: bipolar constant current nerve stimulator and movement detector with a pressure sensor. [2019]
New methodology for facial nerve monitoring in extracranial surgeries of vascular malformations. [2018]
Facial Nerve Branching Patterns Vary With Vascular Anomalies. [2020]